Which has stronger valuation and earnings, KZIA or QNCX?

Novogen has higher revenue and earnings than Quince Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $1.23M 97.75 -$13.41M N/A N/A Quince Therapeutics N/A N/A -$83.98M -$156.71 N/A

Is KZIA or QNCX more profitable?

Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Quince Therapeutics N/A N/A -133.84%

Is INO or QNCX more profitable?

Quince Therapeutics' return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Inovio Pharmaceuticals N/A -669.94% -73.97% Quince Therapeutics N/A N/A -133.84%

Does the media prefer INO or QNCX?

In the previous week, Quince Therapeutics had 2 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 5 mentions for Quince Therapeutics and 3 mentions for Inovio Pharmaceuticals. Quince Therapeutics' average media sentiment score of 0.56 beat Inovio Pharmaceuticals' score of 0.52 indicating that Quince Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quince Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to QNCX or COYA?

In the previous week, Quince Therapeutics had 4 more articles in the media than Coya Therapeutics. MarketBeat recorded 5 mentions for Quince Therapeutics and 1 mentions for Coya Therapeutics. Quince Therapeutics' average media sentiment score of 0.56 beat Coya Therapeutics' score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, QNCX or OKUR?

OnKure Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quince Therapeutics N/A N/A -$83.98M -$156.71 N/A OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A

Is QNCX or OKUR more profitable?

Quince Therapeutics' return on equity of 0.00% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -133.84% OnKure Therapeutics N/A -49.01% -45.77%

Does the media favor QNCX or OKUR?

In the previous week, Quince Therapeutics had 4 more articles in the media than OnKure Therapeutics. MarketBeat recorded 5 mentions for Quince Therapeutics and 1 mentions for OnKure Therapeutics. Quince Therapeutics' average media sentiment score of 0.56 beat OnKure Therapeutics' score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is QNCX or CBUS more profitable?

Quince Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Quince Therapeutics' return on equity of 0.00% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -133.84% Cibus -2,258.89% -287.03% -27.99%

Does the media prefer QNCX or CBUS?

In the previous week, Quince Therapeutics and Quince Therapeutics both had 5 articles in the media. Quince Therapeutics' average media sentiment score of 0.56 beat Cibus' score of 0.18 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cibus 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Quince Therapeutics (QNCX) Competitors

$29.20 -1.48 (-4.82%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$29.42 +0.22 (+0.75%)

As of 10/2/2026 07:30 PM Eastern

Compare

QNCX vs. KZIA, INO, COYA, OKUR, and CBUS

Should you buy Quince Therapeutics stock or one of its competitors? Quince Therapeutics's main competitors and comparable companies include Novogen (KZIA), Inovio Pharmaceuticals (INO), Coya Therapeutics (COYA), OnKure Therapeutics (OKUR), and Cibus (CBUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Quince Therapeutics compare to Novogen?

Novogen (NASDAQ:KZIA) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Novogen currently has a consensus target price of $28.80, indicating a potential upside of 210.68%. Quince Therapeutics has a consensus target price of $206.71, indicating a potential upside of 607.93%. Given Quince Therapeutics' higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Quince Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.62

30.9% of Novogen shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 5.6% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Quince Therapeutics had 5 more articles in the media than Novogen. MarketBeat recorded 5 mentions for Quince Therapeutics and 0 mentions for Novogen. Quince Therapeutics' average media sentiment score of 0.56 beat Novogen's score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Novogen	Neutral
Quince Therapeutics	Positive

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Quince Therapeutics	N/A	N/A	-133.84%

Novogen has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the broader market.

Novogen has higher revenue and earnings than Quince Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$1.23M	97.75	-$13.41M	N/A	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A

Summary

Novogen and Quince Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Quince Therapeutics compare to Inovio Pharmaceuticals?

Inovio Pharmaceuticals (NASDAQ:INO) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Quince Therapeutics' return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
Quince Therapeutics	N/A	N/A	-133.84%

Quince Therapeutics has lower revenue, but higher earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,999.07	-$84.95M	-$0.91	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A

In the previous week, Quince Therapeutics had 2 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 5 mentions for Quince Therapeutics and 3 mentions for Inovio Pharmaceuticals. Quince Therapeutics' average media sentiment score of 0.56 beat Inovio Pharmaceuticals' score of 0.52 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quince Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inovio Pharmaceuticals currently has a consensus target price of $3.17, indicating a potential upside of 172.99%. Quince Therapeutics has a consensus target price of $206.71, indicating a potential upside of 607.93%. Given Quince Therapeutics' higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Quince Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.62

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 5.6% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Inovio Pharmaceuticals has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

Summary

Quince Therapeutics beats Inovio Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Quince Therapeutics compare to Coya Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Quince Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Quince Therapeutics' return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
Coya Therapeutics	-270.22%	-52.05%	-46.34%

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 5.6% of Quince Therapeutics shares are held by insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Quince Therapeutics had 4 more articles in the media than Coya Therapeutics. MarketBeat recorded 5 mentions for Quince Therapeutics and 1 mentions for Coya Therapeutics. Quince Therapeutics' average media sentiment score of 0.56 beat Coya Therapeutics' score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quince Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

Coya Therapeutics has higher revenue and earnings than Quince Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
Coya Therapeutics	$7.95M	14.19	-$21.23M	-$1.07	N/A

Quince Therapeutics presently has a consensus price target of $206.71, indicating a potential upside of 607.93%. Coya Therapeutics has a consensus price target of $15.33, indicating a potential upside of 218.78%. Given Quince Therapeutics' higher possible upside, equities analysts clearly believe Quince Therapeutics is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.62
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Quince Therapeutics beats Coya Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Quince Therapeutics compare to OnKure Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

In the previous week, Quince Therapeutics had 4 more articles in the media than OnKure Therapeutics. MarketBeat recorded 5 mentions for Quince Therapeutics and 1 mentions for OnKure Therapeutics. Quince Therapeutics' average media sentiment score of 0.56 beat OnKure Therapeutics' score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quince Therapeutics presently has a consensus price target of $206.71, indicating a potential upside of 607.93%. OnKure Therapeutics has a consensus price target of $17.50, indicating a potential upside of 583.59%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Quince Therapeutics is more favorable than OnKure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.62
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 5.6% of Quince Therapeutics shares are held by company insiders. Comparatively, 2.2% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

OnKure Therapeutics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

Quince Therapeutics' return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
OnKure Therapeutics	N/A	-49.01%	-45.77%

Quince Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market.

Summary

Quince Therapeutics beats OnKure Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Quince Therapeutics compare to Cibus?

Quince Therapeutics (NASDAQ:QNCX) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 33.8% of Cibus shares are held by institutional investors. 5.6% of Quince Therapeutics shares are held by insiders. Comparatively, 29.9% of Cibus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Quince Therapeutics presently has a consensus price target of $206.71, suggesting a potential upside of 607.93%. Cibus has a consensus price target of $9.00, suggesting a potential upside of 426.32%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Quince Therapeutics is more favorable than Cibus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.62
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Quince Therapeutics has higher earnings, but lower revenue than Cibus. Cibus is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A
Cibus	$3.64M	35.91	-$127.08M	-$1.65	N/A

Quince Therapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Quince Therapeutics' return on equity of 0.00% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-133.84%
Cibus	-2,258.89%	-287.03%	-27.99%

In the previous week, Quince Therapeutics and Quince Therapeutics both had 5 articles in the media. Quince Therapeutics' average media sentiment score of 0.56 beat Cibus' score of 0.18 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cibus	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quince Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market. Comparatively, Cibus has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Summary

Quince Therapeutics beats Cibus on 9 of the 15 factors compared between the two stocks.

Get Quince Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNCX vs. The Competition

Export

Metric	Quince Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$29.70M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-0.19	13.06	275.66	26.04
Price / Sales	N/A	1,292.11	608.92	91.72
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	-0.23	16.63	10.93	6.31
Net Income	-$83.98M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-5.81%	-2.99%	-2.00%	-1.66%
1 Month Performance	-6.77%	-10.81%	-6.19%	-4.68%
1 Year Performance	-91.15%	19.19%	8.03%	1.57%

Quince Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNCX Quince Therapeutics	3.6555 of 5 stars	$29.20 -4.8%	$206.71 +607.9%	-91.2%	$29.70M	N/A	N/A	38	News Coverage Analyst Forecast High Trading Volume
KZIA Novogen	3.4983 of 5 stars	$9.60 +0.3%	$27.33 +184.7%	+41.3%	$124.11M	$1.23M	N/A	6
INO Inovio Pharmaceuticals	2.7559 of 5 stars	$1.17 -0.8%	$3.17 +170.7%	-52.3%	$122.01M	$60K	N/A	112
COYA Coya Therapeutics	1.6137 of 5 stars	$4.98 -2.0%	$15.33 +207.9%	-21.1%	$119.17M	$7.95M	N/A	8
OKUR OnKure Therapeutics	2.3157 of 5 stars	$2.76 -4.8%	$17.50 +534.1%	-5.5%	$117.15M	N/A	N/A	45	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNCX) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quince Therapeutics (QNCX) Competitors

QNCX vs. KZIA, INO, COYA, OKUR, and CBUS

How does Quince Therapeutics compare to Novogen?

Summary

How does Quince Therapeutics compare to Inovio Pharmaceuticals?

Summary

How does Quince Therapeutics compare to Coya Therapeutics?

Summary

How does Quince Therapeutics compare to OnKure Therapeutics?

Summary

How does Quince Therapeutics compare to Cibus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quince Therapeutics (QNCX) Competitors

QNCX vs. KZIA, INO, COYA, OKUR, and CBUS

How does Quince Therapeutics compare to Novogen?

Do analysts prefer KZIA or QNCX?

Do insiders & institutionals believe in KZIA or QNCX?

Does the media refer more to KZIA or QNCX?

Is KZIA or QNCX more profitable?

Which has more risk and volatility, KZIA or QNCX?

Which has stronger valuation and earnings, KZIA or QNCX?

Summary

How does Quince Therapeutics compare to Inovio Pharmaceuticals?

Is INO or QNCX more profitable?

Which has higher valuation & earnings, INO or QNCX?

Does the media prefer INO or QNCX?

Do analysts prefer INO or QNCX?

Do institutionals & insiders believe in INO or QNCX?

Which has more volatility & risk, INO or QNCX?

Summary

How does Quince Therapeutics compare to Coya Therapeutics?

Is QNCX or COYA more profitable?

Do institutionals & insiders believe in QNCX or COYA?

Does the media refer more to QNCX or COYA?

Which has more risk & volatility, QNCX or COYA?

Which has preferable earnings and valuation, QNCX or COYA?

Do analysts prefer QNCX or COYA?

Summary

How does Quince Therapeutics compare to OnKure Therapeutics?

Does the media favor QNCX or OKUR?

Do analysts rate QNCX or OKUR?

Do institutionals & insiders have more ownership in QNCX or OKUR?

Which has stronger valuation and earnings, QNCX or OKUR?

Is QNCX or OKUR more profitable?

Which has more volatility and risk, QNCX or OKUR?

Summary

How does Quince Therapeutics compare to Cibus?

Do institutionals and insiders have more ownership in QNCX or CBUS?

Do analysts rate QNCX or CBUS?

Which has higher earnings & valuation, QNCX or CBUS?

Is QNCX or CBUS more profitable?

Does the media prefer QNCX or CBUS?

Which has more volatility & risk, QNCX or CBUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools